Antibacterial agents including histidine kinase inhibitors
An example composition includes a therapeutically effective amount of a histidine kinase inhibitor. The histidine kinase inhibitor includes at least one of a 6-benzo[d]thiazol-2-amine derivative, a purine derivative, an adenine derivative, an adenine-sulfonyl fluoride derivative, a riluzole analog, a riluzole-sulfonyl fluoride derivative, a 6-benzo[d]thiazol-2-amine-sulfonyl fluoride derivative, a 6,6′-oxybis(benzo[d]thiazol-2-amine) derivative, or a 6,6′-oxybis(benzo[d]thiazol-2-amine)-sulfonyl fluoride derivative. An example technique for treating a bacterial infection includes administering a composition comprising a histidine kinase inhibitor to a patient.
1. A composition comprising a therpeutically effective amount of a histidine kinase inhibitor for treating a bacterial infection, wherein the histidine kinase inhibitor comprises a riluzole analog having a structure
where R═Cl, R 1 ═H, R 2 ═H, R 3 ═NH 2 ; or R═CF 3 , R 1 ═H, R 2 ═H, R 3 ═NH 2 ; or R═NH 2 , R 1 ═H, R 2 ═H, R 3 ═CH 3 ; or R═OCH 3 , R 1 ═H, R 2 ═H, R 3 ═NH 2 ; or R═NH 2 , R 1 ═H, R 2 ═H, R 3 ═NH 2 ; or R═NHCH 2 -arylsulfonyl fluoride, R 1 ═H, R 2 ═H, R 3 ═NH 2 ; or R═NHC(O)-arylsufonyl fluoride, R 1 ═H, R 2 ═H, R 3 ═NH 2 .
2. A composition comprising a therapeutically effective amount of a histidine kinase inhibitor for treating a bacterial infection, wherein the histidine kinase inhibitor comprises a 6-benzo[d]thiazol-2-amine derivative having a structure
where R═Cl, OCH 3 , or CF 3 .
3. A composition comprising a therapeutically effective amount of a histidine kinase inhibitor for treating a bacterial infection, wherein the histidine kinase inhibitor comprises a 6,6′-oxybis(benzo[d]thiazol-2-amine) derivative having a structure
where R═COCH 3 or
4. The composition of claim 1 , wherein the composition comprises 0.01%, 0.1%, 1%, 2%, 5%, or 10% (weight/weight) of the histidine kinase inhibitor.
5. The composition of claim 1 , comprising a pharmaceutically acceptable carrier.
6. The composition of claim 5 , wherein the pharmaceutically acceptable carrier comprises one or more of a cream, a lotion, a spray, a gel, an ointment, a paste, a solution, a suspension, an emulsion, a powder, a liquid, or a solid.
7. A formulation comprising the composition of claim 1 , wherein the formulation is topical, injectable, parenteral, or oral.
8. The composition of claim 2 , wherein the composition comprises 0.01%, 0.1%, 1%, 2%, 5%, or 10% (weight/weight) of the histidine kinase inhibitor.
9. The composition of claim 2 , comprising a pharmaceutically acceptable carrier.
10. The composition of claim 9 , wherein the pharmaceutically acceptable carrier comprises one or more of a cream, a lotion, a spray, a gel, an ointment, a paste, a solution, a suspension, an emulsion, a powder, a liquid, or a solid.
11. A formulation comprising the composition of claim 2 , wherein the formulation is topical, injectable, parenteral, or oral.
12. The composition of claim 3 , wherein the composition comprises 0.01%, 0.1%, 1%, 2%, 5%, or 10% (weight/weight) of the histidine kinase inhibitor.
13. The composition of claim 3 , comprising a pharmaceutically acceptable carrier.
14. The composition of claim 13 , wherein the pharmaceutically acceptable carrier comprises one or more of a cream, a lotion, a spray, a gel, an ointment, a paste, a solution, a suspension, an emulsion, a powder, a liquid, or a solid.
15. A formulation comprising the composition of claim 3 , wherein the formulation is topical, injectable, parenteral, or oral.